Arcutis Biotherapeutics, Inc. ARQT Net unrealized gains (losses) on securities still held
Net unrealized gains (losses) on securities still held at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.
The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcutis Biotherapeutics, Inc.'s net unrealized gains (losses) on securities still held.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s net unrealized gains (losses) on securities still held?
- Arcutis Biotherapeutics, Inc. (ARQT) reported net unrealized gains (losses) on securities still held of -$351K in Q1 2026.
- How has Arcutis Biotherapeutics, Inc.'s net unrealized gains (losses) on securities still held changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s net unrealized gains (losses) on securities still held decreased by 156.2% year-over-year, from -$137K to -$351K.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s net unrealized gains (losses) on securities still held?
- Over 2 years (2021 to 2025), Arcutis Biotherapeutics, Inc.'s net unrealized gains (losses) on securities still held has grown at a -9.8% compound annual growth rate (CAGR), from -$253K to -$206K.
- What does net unrealized gains (losses) on securities still held mean?
- This metric reflects the change in the fair value of investment securities held by the company that have not yet been sold. It captures market-driven fluctuations in the value of the company's treasury or investment portfolio. Investors track this to understand the impact of market volatility on the company's balance sheet and overall financial position.